Applications of Itopride Hydrochloride in Industrial Manufacturing

As a manufacturer specializing in pharmaceutical-grade Itopride Hydrochloride, we supply this active pharmaceutical ingredient (API) to validated clients across regulated downstream sectors. Its functional role is primarily found in the prescription pharmaceutical domain, with all applications strictly aligned with international and local manufacturing controls, quality standards, and product-specific process requirements. Below, we present a detailed breakdown of major downstream application scenarios, each reflecting the functional use, compliance framework, industrial formula integration, and resulting end products of Itopride Hydrochloride.

1. Prescription Gastroprokinetic Tablet Formulations

Leading pharmaceutical manufacturers incorporate Itopride Hydrochloride into solid oral dosage forms to address functional dyspepsia and other gastrointestinal motility disorders. The downstream process requires precision-controlled formulation environments to guarantee uniform API distribution, with each batch crossing multiple in-process quality checkpoints to meet regulatory and safety standards before release to the market.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients
• EU GMP Part I & II
• Current Good Manufacturing Practice (cGMP, 21 CFR Parts 210 & 211, FDA)
• European Pharmacopoeia (Ph. Eur.) and Japanese Pharmacopoeia (JP) monographs for active ingredients and oral dosage forms

Typical usage ratio

• 5 mg to 100 mg per tablet, typically 50–90 mg per single daily dose (final formulation concentration adjusted based on target potency and regulatory maximum limits)

Downstream process integration

• Introduced during the blending/mixing phase with excipients, granulation, followed by tableting, film-coating, and packaging under controlled humidity and particle containment conditions

Final product types

• Film-coated prescription tablets in various strengths
• Immediate-release and extended-release (modified release) oral solids
• Blister-packed tablet formats for hospital and retail pharmacy dispensers

2. Effervescent Granule Formulations for Gastrointestinal Therapy

Effervescent granules containing Itopride Hydrochloride are produced by specialized firms to provide rapid onset of action and convenience for specific patient groups. Manufacturing requires strict powder handling, low moisture environments, and quality validation at each stage to maintain product integrity and meet market authorization requirements in both domestic and international pharmaceutical markets.

Industry compliance standards

• WHO GMP guidelines
• China Pharmacopoeia (ChP) standards for effervescent preparations
• GMP Annex 7: Manufacture of Herbal Medicinal Products (where applicable for mixed formulations)
• Pharmaceutical Stability Testing Guidelines (ICH Q1A)

Typical usage ratio

• Typically 10–30 mg per effervescent sachet or dose unit (with adjustment based on target patient profile, typically not exceeding 100 mg daily cumulative dosage)

Downstream process integration

• Added during dry-blending with effervescent agents (citric/tartaric acid, sodium bicarbonate); further processed via compaction and granulation prior to unit dosing and alu/laminate sachet packaging

Final product types

• Effervescent granule sachets for reconstitution
• Unit-dose packs for direct sale in pharmacies and clinical settings

3. Oral Suspension Preparations (Pediatric and Geriatric Markets)

Some regional pharmaceutical plants formulate Itopride Hydrochloride into flavored oral suspension syrups, particularly targeting pediatric, geriatric, or dysphagic patient populations unable to swallow tablets. The process involves high-precision liquid blending, API solubilization, flavor and preservative addition, and stringent microbial and particulate matter controls before release.

Industry compliance standards

• Pharmacopoeial requirements for liquid oral preparations (USP, BP, Ph. Eur.)
• cGMP for pharmaceutical liquids and suspensions (FDA 21 CFR Part 211)
• Guidelines for pediatric pharmaceutical suspensions (EMA, WHO)
• Real-time and accelerated stability programs (ICH Q1A, Q1B)

Typical usage ratio

• 1–5 mg/mL in finished syrup; final strength tailored based on target demographic, with lower dose per 5 mL unit for pediatric products or titratable dosage for elderly

Downstream process integration

• Dissolution and dispersion in purified aqueous media, followed by adjustment of viscosity, pH, and flavor profile; filled in sterilized HDPE or glass bottles and sealed under nitrogen blanket or similar protection

Final product types

• 150 mL and 250 mL syrup/suspension bottles
• Multi-dose pediatric/geriatric suspensions for prescription dispensing

4. Bulk API for Licensed Pharmaceutical Compounders

We supply high-purity Itopride Hydrochloride API to licensed pharmaceutical contract manufacturing organizations (CMOs) and hospital compounders for authorized compounding use in licensed healthcare settings. This application requires not only batch-level quality documentation and Certificate of Analysis (CoA) but also traceability throughout every logistic and quality handover point, supporting integration with compounding aseptic production sites under continuous regulatory inspection.

Industry compliance standards

• USP and Ph. Eur. monographs for Itopride Hydrochloride API
• GMP Part II for bulk API production (FDA, EMA, PMDA)
• National Drug Regulatory Authorities Import/Export Registration (e.g., US FDA DMF Type II)
• Traceability in line with Falsified Medicines Directive (EU FMD)

Typical usage ratio

• Supplied as >99.0% pure bulk API; individual dose strengths compounded to meet site-specific prescription and administration requirements, typically within pharmacopoeial maximum dose guidance

Downstream process integration

• Integrated into compounding workflows for producing small-batch, patient-specific oral or liquid preparations; weighed and processed under laminar flow workstations or small-scale mixers as per sterile or non-sterile requirements

Final product types

• Customized single-patient oral solution bottles
• In-hospital unit dose capsules and suspensions
• Specialty dosage forms for clinical trials or rare indications

5. Reference Standard Supply for Pharmaceutical QC Laboratories

Quality control and research laboratories at established pharmaceutical manufacturers use Itopride Hydrochloride reference standards for method validation, calibration, and routine release testing according to regulatory requirements. These uses support QC of both in-house and contract-manufactured drug products containing the API, ensuring consistency across global finished product batches and support for regulatory dossiers.

Industry compliance standards

• Official pharmacopoeial reference standards (USP, EP, JP)
• ISO/IEC 17025 accredited test laboratories
• ICH Q2(R1) Validation of Analytical Procedures
• GLP Guidelines and Data Integrity Policies

Typical usage ratio

• Used in microgram to milligram quantities for method validation, system suitability, and batch release testing; concentration tailored to analytical method

Downstream process integration

• Prepared as stock solutions for HPLC, GC, and spectroscopy-based analytical assays; integrated into SOP-driven QC workflows at pharmaceutical plant and third-party laboratory level

Final product types

• Analytical reference standards vials and ampoules
• Batch release and stability test records
• Regulatory dossier submission data sets